S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:ACOR

Acorda Therapeutics - ACOR News Today

$0.92
-0.03 (-3.16%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.90
$0.96
50-Day Range
$0.52
$1.00
52-Week Range
$0.26
$2.29
Volume
136,437 shs
Average Volume
305,645 shs
Market Capitalization
$22.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Get Acorda Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.



ACOR Media Mentions By Week

ACOR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ACOR
News Sentiment

0.63

0.69

Average
Medical
News Sentiment

ACOR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ACOR Articles
This Week

2

1

ACOR Articles
Average Week

SourceHeadline
finance.yahoo.com logoAcorda Therapeutics to Present at Sequire Biotechnology Conference
finance.yahoo.com - January 31 at 8:25 PM
MarketBeat logoStockNews.com Upgrades Acorda Therapeutics (NASDAQ:ACOR) to "Buy"
americanbankingnews.com - January 30 at 4:50 AM
MarketBeat logoShort Interest in Acorda Therapeutics, Inc. (NASDAQ:ACOR) Decreases By 8.1%
americanbankingnews.com - January 24 at 7:59 AM
marketwatch.com logoMethyl Salicylate Patches Market Register to Growth by 2023-2027 | Global Revenue and Key Dynamics with Industry Segments
marketwatch.com - January 23 at 2:59 PM
marketwatch.com logoRepeat Expansion Disorders Treatment Market 2023 Expected to Witness the Highest Revenue Growth Over Forecast to 2029
marketwatch.com - January 17 at 7:35 AM
finance.yahoo.com logoAcorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
finance.yahoo.com - January 5 at 6:29 PM
finance.yahoo.com logoAcorda Therapeutics Announces Revised Long-Term Financial Guidance
finance.yahoo.com - December 22 at 11:04 AM
msn.com logoAcorda Therapeutics gets Nasdaq delisting notice, plans to appeal decision
msn.com - December 21 at 5:45 AM
finance.yahoo.com logoAcorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
finance.yahoo.com - December 20 at 8:22 PM
marketwatch.com logoSpinal Cord Trauma Treatment Market 2023 : Manufacturers Strategies, Share Estimation, Future Demand and Regional Growth Dynamics 2028
marketwatch.com - December 9 at 11:05 AM
baystreet.ca logoAcorda Edges up on Making Interest Payment
baystreet.ca - December 5 at 3:34 PM
finance.yahoo.com logoAcorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
finance.yahoo.com - December 5 at 9:02 AM
finance.yahoo.com logoAcorda Therapeutics Third Quarter 2022 Earnings: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)
finance.yahoo.com - November 19 at 7:15 PM
finance.yahoo.com logoAcorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
finance.yahoo.com - November 11 at 12:47 PM
msn.com logoHow Is The Market Feeling About Acorda Therapeutics?
msn.com - November 9 at 5:59 PM
finance.yahoo.com logoAcorda Therapeutics Reports Third Quarter 2022 Financial Results
finance.yahoo.com - November 1 at 9:51 PM
proactiveinvestors.com logoAcorda Therapeutics supplies long-term guidance and business plan in preparation for shareholders meeting
proactiveinvestors.com - November 1 at 9:57 AM
proactiveinvestors.com logoAcorda Therapeutics shares fly after it provides fresh revenue guidance
proactiveinvestors.com - November 1 at 9:57 AM
finance.yahoo.com logoAcorda Therapeutics Provides Long-Term Business Plan and Financial Guidance
finance.yahoo.com - October 27 at 4:55 PM
finance.yahoo.com logoAcorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022
finance.yahoo.com - October 25 at 4:58 PM
finance.yahoo.com logoAcorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.
finance.yahoo.com - October 21 at 7:22 AM
msn.com logoWhy Ericsson Shares Are Trading Lower? Here Are 56 Stocks Moving In Thursday's Mid-Day Session
msn.com - October 20 at 4:06 PM
finance.yahoo.com logoISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split
finance.yahoo.com - October 19 at 7:05 AM
finance.yahoo.com logoAcorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt
finance.yahoo.com - October 18 at 10:05 AM
marketwatch.com logoAcorda Shares Surge Premarket on Ampyra Arbitration Win >ACOR
marketwatch.com - October 17 at 8:30 AM
markets.businessinsider.com logoAcorda Announces $16.5 Mln Award And Royalty/Supply Relief In AMPYRA Arbitration Case With Alkermes
markets.businessinsider.com - October 16 at 10:25 PM
nasdaq.com logoAcorda Withdraws Proposal To Raise Authorized Shares From Special Meeting Of Stockholders
nasdaq.com - October 10 at 11:45 AM
finance.yahoo.com logoAcorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders
finance.yahoo.com - October 10 at 6:44 AM
finanznachrichten.de logoDefence Therapeutics Inc.: Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative
finanznachrichten.de - September 23 at 4:56 PM
finance.yahoo.com logoAcorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
finance.yahoo.com - September 8 at 8:19 PM
nasdaq.com logoAcorda Enters License Agreement For Nepicastat
nasdaq.com - August 29 at 9:14 AM
finance.yahoo.com logoAcorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals
finance.yahoo.com - August 29 at 9:14 AM
nasdaq.com logoAcorda Therapeutics COO Lauren Sabella To Resign
nasdaq.com - August 19 at 12:47 PM
finance.yahoo.com logoAcorda Therapeutics Announces Resignation of Chief Operating Officer
finance.yahoo.com - August 19 at 12:47 PM
seekingalpha.com logoAcorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 3:41 PM
investing.com logoAcorda Therapeutics Misses Q2 EPS by $2.79
investing.com - August 7 at 12:10 AM
seekingalpha.com logoAcorda Therapeutics Non-GAAP EPS of -$3.15, revenue of $31.05M
seekingalpha.com - August 7 at 12:10 AM
finance.yahoo.com logoAcorda Therapeutics Reports Second Quarter 2022 Financial Results
finance.yahoo.com - August 4 at 7:08 PM
morningstar.com logoAcorda Therapeutics Inc Stock Quote ACOR
morningstar.com - July 30 at 6:38 AM
finance.yahoo.com logoAcorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
finance.yahoo.com - July 28 at 6:19 PM
seekingalpha.com logoNano-cap biotech Acorda surges 50% on drug launch in Germany
seekingalpha.com - June 16 at 6:09 PM
finance.yahoo.com logoWhy Acorda Therapeutics Shares Gaining Today?
finance.yahoo.com - June 16 at 1:08 PM
finance.yahoo.com logoEsteve Launches INBRIJA® in Germany
finance.yahoo.com - June 16 at 8:07 AM
markets.businessinsider.com logoAcorda Therapeutics, Inc. Provides Notice of Data Privacy Event
markets.businessinsider.com - June 14 at 9:02 PM
nasdaq.com logoAcorda Therapeutics Now the Least Expensive vs. Cardano This Year
nasdaq.com - May 18 at 6:55 PM
seekingalpha.com logoAcorda Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 14 at 6:52 PM
seekingalpha.com logoAcorda partners with Biopas to sell Parkinson's disease therapy in Latin America
seekingalpha.com - May 11 at 7:32 PM
finance.yahoo.com logoAcorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America
finance.yahoo.com - May 11 at 7:32 PM
finance.yahoo.com logoAcorda Therapeutics Reports First Quarter 2022 Financial Results
finance.yahoo.com - May 11 at 7:32 PM
finance.yahoo.com logoAcorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022
finance.yahoo.com - May 4 at 7:38 PM
Get Acorda Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:ACOR) was last updated on 2/2/2023 by MarketBeat.com Staff